Back
Full-text
Journal article

Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome.

  • Anzengruber F a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Ignatova D a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Schlaepfer T a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Chang YT a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • French LE a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Pascolo S a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Contassot E a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Bobrowicz M a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
  • Hoetzenecker W c Department of Dermatology , University Hospital Linz , Linz , Austria.
  • Guenova E a Department of Dermatology , University Hospital Zurich University of Zurich , Zurich , Switzerland.
Show more…
  • 2019-01-15
Published in:
  • Leukemia & lymphoma. - 2019
CTCL
Sézary syndrome
immune checkpoints
immune exhaustion
immunotherapy
Aged
Antigens, CD
Biomarkers, Tumor
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
Female
Gene Expression Regulation, Neoplastic
Humans
Immunophenotyping
Male
Middle Aged
Receptors, Immunologic
Sezary Syndrome
English In Sézary syndrome (SS) impaired T-cell function and cytokine profile lead to immune evasion. Immune checkpoints non-redundantly regulate immune responses and targeting them is promising. We evaluated the expression of BTLA, CTLA-4, FCRL3, LAG-3, and TIGIT in tumor and non-tumor SS T-cells.Compared to CD4+ T helper cells from ten healthy individuals, tumor cells of eight SS patients had a significant upregulation of BTLA (1.5-fold; p < .0001), FRCL3 (2.2-fold; p < .0028) and TIGIT (2.2-fold; p < .0003) expression. In contrast, we found a reduced expression of LAG-3+ cells in the blood of tumor patients (0.5-fold; p < .0014). Only weak alternations between tumor, non-tumor cells, and healthy controls were observed regarding CTLA-4 (0.5-fold; p < .2022). Our results show a diverse expression pattern of immune-regulatory molecules in SS patients. As these molecules are essential in the regulation of T-cell mediated tumor surveillance and defense, their specific targeting might be of clinical relevance.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/7021
Statistics
Document views: 19 File downloads:
  • Full-text: 0